Electra Therapeutics Announces First Patients Dosed in the SURPASS Phase 2/3 Pivotal Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

The SURPASS study is enrolling patients at research sites across the U.S. and Europe ELA026 targets signal regulatory proteins (SIRP) as a novel approach to treating the life-threatening hyperinflammatory pathology of sHLH SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) — Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for […]

Stifel Reports Third Quarter 2025 Results

(NYSE:SF), ST. LOUIS, Mo., Oct. 22, 2025 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today reported net revenues of $1.4 billion for the three months ended September 30, 2025, compared with $1.2 billion a year ago. Net income available to common shareholders was $202.1 million, or $1.84 per diluted common share, compared with $149.2

Troilus Announces Change of Auditor

(TSX:TLG),(OTC US:CHXMF),(Other OTC:CHXMF),(Boerse Frankfurt – Freiverkehr:CM5R), MONTREAL, Oct. 22, 2025 (GLOBE NEWSWIRE) — Troilus Gold Corp. (TSX: TLG; OTCQX: CHXMF; FSE: CM5R) (“Troilus” or the “Company”) announces that it has changed its auditor from McGovern Hurley LLP (“Former Auditor”) to Deloitte LLP (“Successor Auditor” or “Deloitte LLP”) effective October 21, 2025. The appointment of Deloitte

QuidelOrtho to Report Third Quarter 2025 Financial Results

QuidelOrtho Corporation (Nasdaq: QDEL)(the “Company” or “QuidelOrtho”), a global leader of in vitro diagnostics, announced today that it will report its financial results for the third quarter 2025 ended September 28, 2025, after the market closes on Wednesday, November 5, 2025. https://mma.prnewswire.com/media/2724032/QuidelOrtho_Corporation_Logo.jpg Following the release of financial results, QuidelOrtho will hold a conference call beginning

Enthusiast Gaming Provides Update Regarding Annual General and Special Meeting of Shareholders

(TSX:EGLX),(Boerse Frankfurt – Freiverkehr:2AV.F), TORONTO, Oct. 22, 2025 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading digital publisher focused on building tools, platforms, and experiences for gamers, wishes to provide an update to shareholders regarding the impact of the ongoing strike by the Canadian Union of Postal

Bluwhale Secures $10 Million Strategic Series A in Institutional Funding

SAN FRANCISCO , Oct. 22, 2025 (GLOBE NEWSWIRE) — Bluwhale, the decentralized AI network powering agents on blockchains, today announced the close of its $10 million Series A funding round backed by a global financial institution and top L1/L2 blockchains. The fresh raise underscores the growing trend of institutional adoption of digital assets, as well

Mercury Awarded Contract To Develop Multi-Mission Subsystem for U.S. Military Programs

(NASDAQ:MRCY), ANDOVER, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a global technology company that delivers mission-critical processing to the edge, today announced it was awarded a multi-year, cost-plus-fixed-fee development contract in September to develop a multi-mission, multi-domain subsystem for a U.S. defense prime contractor. “This program will leverage open

Old National Bancorp Reports Third Quarter 2025 Results

(NASDAQ:ONB), EVANSVILLE, Ind., Oct. 22, 2025 (GLOBE NEWSWIRE) — Old National Bancorp (NASDAQ: ONB) reports 3Q25 net income applicable to common shares of $178.5 million, diluted EPS of $0.46; $231.3 million and $0.59 on an adjusted1 basis, respectively. CEO COMMENTARY: “Old National's outstanding quarterly results reflect our continued focus on the fundamentals and the benefits

WindRose Health Investors Completes Sale of BPD Healthcare to MJH Life Sciences

WindRose Health Investors, LLC (“WindRose”), the New York-based healthcare private equity firm, announced that it has completed the sale of BPD Healthcare (“BPD” or the “Company”) to MJH Life Sciences (“MJH”), the largest privately held medical media company in North America. MJH Life Sciences is dedicated to improving patient care through trusted health care communications,

Nanoscope Therapeutics Announces Durable 3-Year Vision Improvements from REMAIN Study of MCO-010 in Retinitis Pigmentosa

— REMAIN results showed sustained, 3-line vision gains vs baseline through 152 weeks for MCO-010 in patients having severe vision loss from retinitis pigmentosa, and a favorable safety profile — The data form the clinical basis of a rolling Biologics License Application, initiated in June 2025, with the potential to be the first FDA-approved optogenetic

Scroll to Top